Obesity and metabolic syndrome in adults with a 22q11.2 microdeletion
November 30, 2024 / 22q11.2 Deletion Syndrome / Metabolic Syndrome / Obesity Prevalence in Genetic Disorders / Endocrine Impacts / Genetic Obesity Risk Factors
Adults with 22q11.2 deletion syndrome have significantly higher rates of generalized obesity, abdominal obesity, and metabolic syndrome. Age strongly correlates with these conditions, highlighting the need for early monitoring and intervention.
Impact of daily fasting duration on body composition and cardiometabolic risk factors during a time-restricted eating protocol: a randomized controlled trial
November 29, 2024 / Time-restricted Eating Benefits / Body Composition and Fasting / Cardiometabolic Health / Fasting Duration Impact
A 16-hour fasting window (TRE 16:8) improved body composition by reducing body mass and fat mass without calorie restriction in healthy individuals, outperforming shorter fasting periods. Other cardiometabolic factors showed no significant changes after 8 weeks.
Human adipose depots’ diverse functions and dysregulations during cardiometabolic disease
November 29, 2024 / Adipose Tissue Functions / Visceral Fat and Cardiometabolic Risk / Brown Adipose Tissue Thermogenesis
Adipose tissue depots have location-specific functions, with dysregulations contributing to cardiometabolic diseases. Visceral fat promotes inflammation and insulin resistance, while subcutaneous and brown fat support metabolic health. Understanding these dynamics aids in addressing cardiometabolic disease progression.
Consensus on the key characteristics of metabolism disruptors
November 29, 2024 / Metabolism-disrupting Agents (MDAs) / Metabolic Disorder Risk Factors / Endocrine Pancreas Dysfunction / Chronic Inflammation in Metabolism
Metabolism-disrupting agents (MDAs) are chemical, infectious, or physical agents that increase metabolic disorder risk. A consensus identifies 12 key characteristics of MDAs, including insulin resistance, disrupted signaling, chronic inflammation, and circadian rhythm disruption, aiding systematic hazard identification.
Adipocyte Adaptation to Stress May Unlock New Therapies for Obesity
November 28, 2024 / Caveolae and Adipocyte Function / Obesity Therapeutic Strategies / Cav-1 Phosphorylation in Fat Cells / Lipodystrophy and Metabolic Syndrome
Caveolae structures in fat cells protect against mechanical stress, enabling safe energy storage and preventing inflammation. Malfunctioning caveolae, linked to caveolin-1 phosphorylation failure, increase the risk of obesity-related diseases, offering new therapeutic targets.
Aggregation of cardiovascular risk factors in a cohort of 40-year-olds participating in a population-based health screening program in Sweden
November 28, 2024 / Cardiovascular Risk in 40-year-olds / Obesity / Heart Health / Non-metabolic Cardiovascular Risk Factors / Psychological Distress and CVD Risk
A Swedish health screening of 40-year-olds revealed obesity/central obesity strongly associates with non-metabolic cardiovascular risk factors, including psychological distress and socioeconomic vulnerability. Screening programs should target obesity while addressing non-metabolic risks for better cardiovascular health outcomes.
The dual GLP-1/glucagon receptor agonist G49 mimics bariatric surgery effects by inducing metabolic rewiring and inter-organ crosstalk
November 28, 2024 / Dual GLP-1 / G49 Obesity Treatment / Metabolic Rewiring and Weight Loss / Bariatric Surgery Alternative Therapy
The dual GLP-1/glucagon receptor agonist G49 mimics bariatric surgery’s metabolic benefits by inducing fat tissue remodeling, increasing energy expenditure, and promoting weight loss through inter-organ crosstalk, offering a promising pharmacological alternative for obesity and diabetes treatment.
Normal weight obesity, circulating biomarkers and risk of breast cancer: a prospective cohort study and meta-analysis
November 28, 2024 / Normal Weight Obesity and Cancer / Postmenopausal Breast Cancer Risk / Inflammation Biomarkers / Breast Cancer
Normal weight obesity (NWO) increases the risk of postmenopausal breast cancer, linked to excess body fat and biomarkers like inflammation markers and β-Hydroxybutyrate. BMI alone may underestimate cancer risks in postmenopausal women.
How genetic traits contribute to earlier diabetes onset and metabolic challenges in South Asians
November 28, 2024 / Type 2 Diabetes in South Asians / Genetic Risks for Early Diabetes / Insulin Deficiency / Lipodystrophy / Diabetes Genetic Profiling
South Asians with genetic risks like beta cell dysfunction and lipodystrophy face earlier type 2 diabetes (T2D) onset, rapid progression, insulin dependence, and poorer treatment response. Genetic profiling reveals key differences influencing diabetes management and complications.
CORRECTING and REPLACING Altasciences Supports Metsera in Their Early-Stage Clinical Trials for Obesity
November 28, 2024 / MET-097i Obesity Treatment / Long-acting GLP-1 Receptor Agonist / Altasciences Clinical Trial Support / Metsera Obesity Research / Obesity Therapeutics
Altasciences supported Metsera in early-stage trials of MET-097i, a long-acting GLP-1 receptor agonist for obesity. Positive Phase I/II results showed significant weight reduction and advanced Phase II trials, highlighting innovative treatments for obesity-related illnesses.
Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)
November 28, 2024 / MASH Treatment Innovations / Semaglutide Metabolic Benefits / Liver Fibrosis Reversal Strategies / MASLD Therapeutic Advancements
Metabolic dysfunction-associated steatohepatitis (MASH) therapies, like resmetirom and semaglutide, target liver function and metabolism. Combining thyroid receptor agonists, fatty acid synthase inhibitors, and incretin analogues may optimize MASH treatment and fibrosis reversal.
Understanding the pathophysiological relationship between OSA and metabolic syndrome
November 27, 2024 / Obstructive Sleep Apnea and MetS / OSA Cardiovascular Risk Factors / CPAP Therapy Metabolic Impact / OSA Obesity and Visceral Fat / Hypertension / Diabetesy
Obstructive sleep apnea (OSA) and metabolic syndrome (MetS) share risk factors like obesity and exacerbate each other, increasing cardiovascular risks. Interventions like CPAP improve OSA symptoms but have limited effects on metabolic dysfunctions, requiring combined treatment strategies.
Novel Thyroid Hormone Receptor Agonists Show Promise for MASH
November 27, 2024 / MASH Thyroid Receptor Agonists / VK2809 Liver Fat Reduction / Steatohepatitis Therapy / Fibrois Improvement in MASH / Innovative Fatty Liver Treatments
Thyroid hormone receptor agonists VK2809 and ALG-055009 show promise for metabolic dysfunction-associated steatohepatitis (MASH), demonstrating significant liver fat reduction, MASH resolution, and fibrosis improvement in clinical trials, with potential cardiovascular benefits and good tolerability.
Amgen Announces Robust Weight Loss with MariTide in People Living With Obesity of Overweight at 52 weeks in a Phase 2 Study
November 26, 2024 / MariTide Obesity Treatment / Amgen Weight Loss Therapy / Long-term Obesity Management / Cardiometabolic Improvements in Obesity
Amgen’s investigational obesity treatment, MariTide, demonstrated up to 20% weight loss at 52 weeks without plateau, significant HbA1c reductions in diabetes patients, and improved cardiometabolic health. MariTide’s monthly dosing shows promise for long-term obesity management.
Tirzepatide Shows Powerful Diabetes-Prevention Effect in Three-Year Trial
November 26, 2024 / Tirzepatide Diabetes Prevention / Zepbound Weight-loss Drugs / GLP-1 and GIP Dual Agonist / Prediabetes Treatment Breakthrough / Surmount-1 Trial Outcomes
Tirzepatide reduced type 2 diabetes progression by over 90% in obese, prediabetic patients over three years. It promotes weight loss and improves blood sugar control via GLP-1 and GIP receptor activation, showing promise for diabetes prevention.
Amgen obesity drug cuts weight in study, but results miss Wall Street’s high mark
November 26, 2024 / MariTide Phase 2 Results / Amgen Obesity Drug Trials / GLP-1 and HIP Inbitors
Amgen’s MariTide achieved up to 20% weight loss in Phase 2 trials, comparable to leading obesity drugs. While offering monthly dosing, it showed higher dropout rates due to side effects, raising questions about its competitiveness against established treatments.
New discovery in the peripheral nervous system could help control obesity
November 25, 2024 / Neuropeptide Y and Obesity / Peripheral Nervous System Metabolism / Brown Adipocyte Thermogenesis / Novel Anti-Obesity Drug Targets / Weight Control
Researchers identified a new peripheral nervous system component that regulates energy metabolism via neuropeptide Y (NPY). Unlike brain-targeted therapies, this discovery could lead to simpler, cost-effective anti-obesity drugs by enhancing fat-burning brown and beige adipocytes.
How neural and hormonal gut-brain communication shapes metabolism and health
November 25, 2024 / Gut-Brain Communication Pathways / Interoception and Metabolism / GLP-1 and Metabolic Requlation
Gut-brain communication via neural, hormonal, and microbial pathways regulates metabolism and homeostasis. Disruptions in these mechanisms contribute to obesity, diabetes, and neuropsychiatric disorders, offering therapeutic potential, such as GLP-1-based treatments for metabolic diseases.
Thyroid hormone receptor-beta agonist achieves ‘robust reduction’ in liver fat in MASH
November 25, 2024 / VK2809 Liver Fat Reduction / MASH Resolution Therapy / Thyroid Receptor-beta Agonists / Cardioprotective Obesity Treatments
VK2809, a thyroid hormone receptor-beta agonist, significantly reduced liver fat, achieved MASH resolution, and improved fibrosis by week 52 in MASH patients. The treatment demonstrated durability, cardioprotective potential, and favorable tolerability in clinical trials.